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Obtaining the target blood pressure level by monotherapy can be challenging currently,
especially for the patients who are suffering from other diseases meanwhile. It is
demonstrated that a majority of hypertensive patients need two or more antihypertensive
drugs to lower their blood pressure effectively. Consequently, fixed-dose which can be
defined as that several active agents were combined in single pharmaceutical formulations
appears to be a novel and underlying power in overcoming the cardiovascular disease.
Based on the analysis of some literature and relative data from FDA, the advantages of
fixed-dose combination are elucidated and formulations of common dual, triple-
combinations were summarized. Clinical practices proved that fixed-dose combinations
had many benefits comparing with single drug and separate agents in terms of effects,
convenience, compliance, and costs to a certain extent. From the patients’ perspective, the
fixed-dose combination therapy will be increasingly utilized in blood pressure control in
the future.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Hypertension, a common cardiovascular disease, should take
themost responsibility for themorbidity andmortality caused
by disease in the world every year. Hypertension is the pri-
mary cause of cardiovascular disease (CVD) and deaths glob-
ally [1]. Report from the American Heart Association showed522.
.com (X. Wan), zhangxr@
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univthat based on 2007e2010 data, 33.0% of US adults 20 years of
age were in hypertension [2]. According to an incomplete
statistics in the year of 2001, the mortality induced by hyper-
tension takes the proportions of 12.5%e14.2% in the total fa-
talities in the world [3]. Although people have made
substantial efforts in blood pressure control and got great
achievement accordingly, we also have a longway on the pathvip.sina.com (X. Zhang).
sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
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practice. As early as 1999, WHO/ISH guidelines [4] have rec-
ommended the monotherapy from six classes and fixed-dose
with the definition of combining two or more active agents in
a single pharmaceutical formulation for the initial treatment
of hypertension. Statistics shows that only a minority of hy-
pertension patients can obtain rational blood pressure by
monotherapy, that is to say, most patients need combination
therapy to control their disease. A survey on the trends in the
use of antihypertensive agents in France from 2002 to 2012
supported the view mentioned above with the result that the
prescriptions of fixed-dose combinations increased from 19%
to 30% [5]. Combination therapy can be two or more agents
administered separately or in a fixed-dose combination
dosing, and the latter seems to be more popular in clinical
practice based on its advantages in terms of convenience,
cost, compliance, efficacy and aggressive effects.2. Advantages of fixed-dose combinations
2.1. Monotherapy versus combination therapy
A number of clinical trials show that most hypertensive pa-
tients were unlikely to achieve a normal blood pressure by
taking single drug for a quite long term. Hence, doctors tend to
give a higher dose at the first time, however, high dose therapy
usually only bring a modest antihypertensive effect stepped
with some severe side effects [6], supporting the perspective
that patients may not obtain more at a higher dose when a
drug can’t meet their needs at a recommended dose [7].2.2. Combination therapy with separate agents versus
fixed-dose combinations
Combination therapy rises as an alternative for the patients
who fail to lower their blood pressure bymonotherapy or who
are in co-morbidities conditions. Combination therapy was
classified into two kinds: one is various drugs were prescribed
separately; the other is drugs in fixed-dose combinations.
Undoubtedly, the former brought much trouble for the pa-
tients especially the elders who were tired of taking a series of
pills every day. But the fixed-dose combination can solve this
problemwell by offering a relative simple regimen with fewer
pills or once-daily dosing. Anyway, patients suffering a
chronic disease like hypertension prefer simple prescribing
program. Although fixed-dose formulations are still in suspi-
cious by physicians in some areas, it should be acknowledged
that fixed-dose in combination is a natural trend in the history
of improving the blood pressure control. Some rational fixed-
dose formulations have been widely practiced in treating
other disease such as type 2 diabetes mellitus (sitagliptin and
metformin) [8] and so on.2.3. Fixed-dose combinations
When monotherapy was replaced by fixed-dose combination
pills, one may ask whether fixed-dose formulations can offer
enough advantages to defeat traditional monotherapy. Fixed-dose combination pill as a promising choice to hypertensive
patients may have some potential superiorities as follows:
Firstly, fixed-dose formulations usually can give patients
some surprising effects comparing with only taking anyone
ingredient of the combinations. Fixed-dose combinations
sometimes may provide a synergistic effect in a perfect
combination except the usual addictive effect. Since drugs in
formulations from different classes exert their effects based
on individual mechanism with different action sites and ac-
tion time, fixed-dose combinations in hypertension have a
potential for a modest and long term action. Clinical trials
demonstrated that angiotensin II receptor blockers (ARB) such
as valsartan can minimize the peripheral edema caused by a
calcium channel blocker such as amlodipine [9], which is in
concert with the notion that combining two antihypertensive
agents from different classes in a formulation in many cases
may partly offset the adverse effects from each other. Besides,
all the side effects from drugs in combination can also be
decreased because of the low dose. In summary, for rational
fixed-dose combinations, they may control hypertension well
without additional side effects. Matthew R. Weir et al. [10]
conducted a titrate-to-goal study by switching patients who
can’t obtain target blood pressure level on monotherapy to
fixed-dose combinations of amlodipine and olmesartan
medoxomil  hydrochlorothiazide with a satisfying result
that the majority of subjects achieved blood pressure goals
without suffering severe adverse effects.
Next, there is a psychological problem must be taken into
consideration in treating the chronic disease. Since most hy-
pertension patients are elders who have poor memory and
can’t act easily, the convenience and compliance brought by
therapy are especially important. A mete-analysis based on a
certain number of database demonstrated that fixed-dose
combinations brought a tremendous improvement in compli-
ance and persistence for the treatment of hypertension [11].
Combination therapy with fixed-dose usually can exhibit its
effects with fewer pills or once-daily dosing formulation, then
improve patients compliance and psychological state largely.
At last, cost may also be an obstacle in blood pressure
control for part patients. Combination therapywith fixed-dose
may be less costly than the drugs administered separately,
what’smore, combination therapymay reduce the prescribing
costwith fewermedications andoffer thepoorpatients a lower
overall health care costs. Statistical analysis shows that the
cost of angiotensin-converting enzyme inhibitors (ACEI)/ARB
and thiazide diuretics administered in single combination
products can bring a cost-saving about $27e45million per year
for the Canadian health care system than drugs administered
separately [12]. Fig. 1 showed advantages of fixed-dose com-
binations versus monotherapy and separate agents.3. Common combinations
There are several common drug classes can be used in tack-
ling hypertension: thiazide diuretics, calcium channel
blockers (CCB’s), beta(b)-blockers, alpha(a)-blockers, ACEI,
ARB and some centrally acting drugs. Table 1 showed fixed-
dose combination products approved by FDA from 2003 to
2013 including dual combinations and triple-combination.
Fig. 1 e Advantages of fixed-dose combinations versus monotherapy and separate agents.
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Since the use of fixed-dose combinations in hypertension is
being a new trend and method in clinical practice, more and
more combination products were developed especially the
drugs comprising of thiazide diuretics and ACEI/ARB. When
elderly patients treated with ACEI alone fail to achieve ideal
blood pressure, fixed-dose combinations consist of thiazide
diuretics and ACEI can often perform a favorable effect
demonstrating that thiazide diuretics and ACEI can make up
an almost ideal group. Diuretics would induce increased so-
dium loss and intravascular volume depletion when exerting
their effects which can lead to an activation of
renineangiotensinealdosterone system (RAAS) thus boosting
the antihypertensive effect of ACEI. Study in uncontrolled
hypertensive patients with a fixed-dose combination of ram-
ipril/hydrochlorothiazide certified the powerful effects of
combinations mentioned above [13]. Based almost the same
mechanism, the combination of thiazide diuretics and ARB
shows an additive antihypertensive effect. Stepped with the
selective inhibition of ARB on angiotensin II, the antihyper-
tensive effect of thiazide diuretics was enhanced greatly. ARB
also can reduce the potassium loss and hyperuricemia caused
by thiazide diuretics owing to the interdiction of aldosterone
secretion. The combination of losartan with hydrochlorothi-
azide has been widely used in China since 2008, and studies
attested that this combination has a stable long-term anti-
hypertensive effect in patients whose blood pressure can’t be
controlled with ARB or combinations with a CCB [14]. The
combination of candesartan and hydrochlorothiazide was
also demonstrated to be an excellent alternative in treating
hypertension for its outstanding efficacy and tolerability [15].
Fixed-dose combinations of ARB and thiazide diuretics not
only exerted a superior efficacy but also maintained the
outstanding tolerability profile of the ARB in clinical practice.
3.2. Thiazide diuretics plus b-blockers
As the based antihypertensive drugs, thiazide diuretics also
can be combined with b-blockers. It is known that b-blockers
can reduce cardiac output, inhibit the secretion of renin and
weaken the function of peripheral sympathetic and thusobtain antihypertensive effects. Owing to the inhibition of the
production of renin and angiotensin II brought by b-blockers,
combinations of these two agents exhibit a significant
reduction in side effects caused by thiazide diuretics such as
intravascular volume depletion and total body sodium loss.
The first fixed-dose formulation consists of bisoprolol and
hydrochlorothiazide was marketed in china in April 2007, and
it was recommended by JVC V and JVC VI as the first-line drug
for treating hypertension. Recent trial results showed that
fixed-dose combination of nebivolol and hydrochlorothiazide
was effective in controlling blood-pressure levels without a
side effect on glucose and lipid profile during the study period
[16].3.3. b-blockers plus CCB’s
Calcium channel blockers as an important class of antihy-
pertensive drugs can selectively block voltage-dependent
calcium channels, relax the vascular smooth muscle, reduce
peripheral vascular resistance, and so get blood pressure
drops. According to the different chemical structures, CCB’s
are categorized into two classes namely dihydropyridine and
non-dihydropyridine. It is reported that the non-
dihydropyridine CCB’s including verapamil and diltiazem
cannot combine with b-blockers because of the occurrence of
symptomatic bradycardia and atrioventricular block [7].
However, the integration of b-blockers and dihydropyridine
CCB’s can be ideal combinations. The control of renin level
due to b-blockers will reinforce the vasodilatory properties,
thus achieving synergistic antihypertensive effects.3.4. b-blockers plus ACEI/ARB
Early trials have attested that adding a b-blocker to an ACEI
did not offer more superiority in lowering blood pressure than
single therapy with ACEI [17]. The result may be explained by
their antihypertensive mechanism. ACEI can be applied to all
types of hypertension especially in normal or high-renin state,
which may conflict with the inhibition of renin level induced
by b-blockers. Literature also reported that combinations of
renineangiotensinealdosterone system blockers and beta-
Table 1 e Fixed-dose combination products approved by FDA from 2003 to 2013.
Trade name Active ingredients Formulations Specifications
(mg)
Approval
date
Applicants
Benicar HCT Hydrochlorothiazide/olmesartan
medoxomil
Tablet 12.5/20 2003-6-5 Daiichi Sankyo Inc
12.5/40
25/40
Exforge Amlodipine besylate/valsartan Tablet 5/160 2007-6-20 Novartis
Pharmaceuticals
Corp
5/320
10/160
10/320
Azor Amlodipine besylate/olmesartan
medoxomil
Tablet 5/20 2007-9-26 Daiichi Sankyo Inc
5/40
10/20
10/40
Tekturna HCT Aliskiren hemifumarate/
hydrochlorothiazide
Tablet 150/12.5 2008-1-18 Novartis
Pharmaceuticals
Corp
150/25
300/12.5
300/25
Valturna Aliskiren hemifumarate/valsartan Tablet 150/160 2009-9-16 Novartis
Pharmaceuticals
Corp
300/320
Exforge HCT Amlodipine/hydrochlorothiazide/
valsartan
Tablet 5/12.5/160 2009-4-30 Novartis
Pharmaceuticals
Corp
5/25/160
10/12.5/160
10/25/160
10/25/320
Twynsta Amlodipine besylate/telmisartan Tablet 5/40 2009-10-16 Boehringer
Ingelheim
Pharmaceuticals
Inc
5/80
10/40
10/80
Losartan
potassium and
hydrochlorothiazide
Hydrochlorothiazide/losartan
potassium
Tablet 12.5/100 2010-4-6 Teva Pharms
12.5/50
25/100
Tribenzor Amlodipine besylate/
hydrochlorothiazide/olmesartan
medoxomil
Tablet 10/12.5/40 2010-7-23 Daiichi Sankyo
10/25/40
5/12.5/20
5/12.5/40
5/25/40
Tekamlo Aliskiren hemifumarate/amlodipine
besylate
Tablet 150/10 2010-8-26 Novartis
150/5
300/10
300/5
Trandolapril and
verapamil
hydrochloride
Trandolapril/verapamil
hydrochloride
Tablet,
extended
release
1/240 2010-8-30 Glenmark
Generics2/180
2/240
4/240
Amturnide Aliskiren hemifumarate/amlodipine
besylate/hydrochlorothiazide
Tablet 150/5/12.5 2010-12-21 Novartis
300/10/12.5
300/10/25
300/5/12.5
300/5/25
Irbesartan;
hydrochlorothiazide
Irbesartan/hydrochlorothiazide Tablet 150/12.5 2011-2-16 Zydus Pharms
USA Inc300/12.5
300/25
Amlodipine besylate;
olmesartan medoxomil
Amlodipine besylate/olmesartan
medoxomil
Tablet 10/20 2011-3-7 Matrix Labs Ltd
10/40
5/20
5/40
Olmesartan medoxomil;
hydrochlorothiazide
Olmesartan medoxomil/
hydrochlorothiazide
Tablet 20/12.5 2011-4-15 Mylan Pharma
40/12.5
40/25
Amlodipine besylate;
benazepril hydrochloride
Amlodipine besylate/benazepril
hydrochloride
Capsule 10/40 2011-7-5 Lupin Pharms
Telmisartan;
hydrochlorothiazide
Telmisartan/hydrochlorothiazide Tablet 40/12.5 2011-9-15 Watson Labs
Florida80/12.5
80/25
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Table 1 e (continued )
Trade name Active ingredients Formulations Specifications
(mg)
Approval
date
Applicants
Edarbyclor Azilsartan kamedoxomil/
chlorthalidone
Tablet 40/12.5 2011-12-20 Takeda Pharms
USA40/25
Irbesartan and
hydrochlorothiazide
Hydrochlorothiazide/irbesartan Tablet 12.5/150 2012-3-30 Teva
12.5/150
12.5/300
12.5/300
25/300
Valsartan;
hydrochlorothiazide
Valsartan/hydrochlorothiazide Tablet 160/12.5 2012-4-10 Torrent Pharms
Ltd160/25
320/12.5
320/25
80/12.5
Valsartan and
hydrochlorothiazide
Hydrochlorothiazide/valsartan Tablet 12.5/160 2012-9-21 Mylan Pharms
Inc12.5/320
12.5/80
25/160
25/320
Amlodipine, valsartan and
hydrochlorothiazide
Amlodipine/hydrochlorothiazide/
valsartan
Tablet 10/12.5/160 2012-9-25 Teva Pharms
10/25; /60
10/25/320
5/12.5/160
5/25/160
Hydrochlorothiazide;
Irbesartan
Hydrochlorothiazide/irbesartan Tablet 12.5/150 2012-9-28 Cipla Limited
12.5/300
Irbesartan
hydrochlorothiazide
Hydrochlorothiazide/irbesartan Tablet 25/300 2012-10-15 Apotex Inc
Candesartan cilexetil and
hydrochlorothiazide
Candesartan cilexetil/
hydrochlorothiazide
Tablet 16/12.5 2012-12-4 Mylan Labs
32/12.5
32/25
Candesartan cilexetil;
hydrochlorothiazide
Candesartan cilexetil/
hydrochlorothiazide
Tablet 16/12.5 2012-12-11 Teva Pharms USA
32/12.5
32/25
Amlodipine besylate and
valsartan
Amlodipine besylate/valsartan Tablet 10/160 2013-3-28 Par Pharm Inc
10/320
5/160
5/320
Amlodipine; valsartan;
hydrochlorothiazide
Amlodipine/valsartan/
hydrochlorothiazide
Tablet 10/160/12.5 2013-4-18 Par Pharm Inc
10/160/25
10/320/25
5/160/12.5
5/160/25
Amlodipine besylate;
valsartan
Amlodipine besylate/valsartan Tablet 10/160 2013-4-29 Lupin Ltd
10/320
5/160
5/320
Telmisartan; amlodipine Telmisartan/amlodipine Tablet 40/10 2013-5-28 Lupin Ltd
40/5
80/10
80/5
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compared with either single therapy [18].
3.5. CCB’s plus ACEI/ARB
ACEI and ARB belong to the inhibitors of
renineangiotensinealdosterone system (RAAS). Calcium
channel blockers as potent antihypertensive agents will
sensitize the renineangiotensinealdosterone system (RAAS)
and therefore lead to an improvement of renin state, which
will enhance the antihypertensive effects of ACEI/ARBwithout doubt. In addition to their improvement in effects,
many combinations of CCB’s and ACEI also applied to patients
with comorbid conditions. Previous study on the fixed-dose
combinations of lercanidipine plus enalapril demonstrated
that this combination provide an encouraging renal protec-
tion for patients with chronic renal failure [19]. Additionally,
research on trandolapril/verapamil combination showed that
this formulation may be an optimal alternative for the treat-
ment of hypertensive patients with diabetes [20]. Combina-
tions of agents from CCB’s and ARB respectively also brought
much surprise for patients with elevated blood pressure, this
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 1e76theory can be supported by an uncontrolled study on combi-
nation of olmesartan and amlodipinewith the conclusion that
the formulation was effective and well-tolerated in initial
treatment [21]. Study on the initial therapy effect of fixed-dose
product amlodipine/valsartan and single drug amlodipine in
black patients with stage 2 hypertension demonstrated that
the former exhibited a greater and faster blood-pressure
reduction [22].
3.6. Triple fixed-dose combinations
When patients can’t obtain target blood pressure with two
drugs in combination, there are triple fixed-dose combina-
tions to choose. Three-in-one fixed-dose combination of
reserpine, apresoline and hydrochlorothiazide was the first
triple fixed-dose formulation to be marketed in US, which
exhibit obvious advantages over placebo in trial. Tribenzor, a
triple fixed-dose combination consisting of amlodipine,
olmesartan medoxomil and hydrochlorothiazide, was
approved by FDA in July 2010, and trial certificated that the
formulation can provide an effective and safe hypertension
control in obese patients [23] except the normal hypertensive
patients. Researches on the triple therapy exhibit that this
prescription with less pills may improve adherence and clin-
ical outcomes without increasing cost [24]. There are also
other triple fixed-dose combinations arising such as Exforge
HCT (amlodipine þ valsartan þ hydrochlorothiazide;
Novartis Pharmaceuticals, East Hanover, NJ), and Amturnide
(amlodipineþ aliskirenþ hydrochlorothiazide; Novartis), thus
three-in-one combinations with fixed-dose seem to have a
huge market prospect in the near future.4. Dosage form of fixed dose combination
There are many types of fixed dose combinations comprising
oral, inhalation and parental on market in manymedical field
[25]. Among the common types, oral dosage forms of tablet
and capsule provide simplified treatment regimens, greater
patient convenience and compliance. Formulation technolo-
gies such as multi-layer tablets, multiparticulate systems,
active film coating, and hot-melt granulation are developed in
the design of formulation. Reviews of the Physicians’ Desk
Reference (PDR) show that infections, cardiovascular, hor-
mone, allergies and pain are the top five medical areas for
fixed dose combinations of oral dosage forms, nevertheless
hypertension treatment takes 80% in cardiovascular [26].5. Precautions of the applications of fixed-
dose combinations
In spite of proven benefits of fixed-dose combinations in
treating hypertension, there are some problems should be
considered in applying them. Practically, some products of
fixed-dose combinations are widely used in the area of hy-
pertension, however some others are unnecessary and even
brought negative effects in some cases [27]. Firstly, rational
combinations of different agents should be chose based on
the complementary pharmaceutical mechanisms or theeffective prohibition of the counter-regulatory response [28].
Next, safety can be a key point to consider during the appli-
cation of fixed-dose combinations. The prescription of com-
bination products consisting of aliskiren (ALI) ACEI and ARB
was warned of possible drawbacks by the FDA when using
then in patients with complications of diabetes or renal
impairment [29].6. Conclusion
When monotherapy encountered bottlenecks in treating hy-
pertension, fixed-dose combinations were recommended as
an effective and safe regimen for initiating therapy especially
for the patients with complications. Each drug in perfect
combination will exert its best effectiveness with fewer side
effects. Additionally, fixed-dose combinations also brought
economical benefits for patients with fewer medications
compared with several drugs administered separately. Based
on the clinical practice and market research, fixed-dose for-
mulations are becoming a promising choice for hypertensive
patients gradually.r e f e r e n c e s
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